Phase i evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies

European Journal of Cancer

Volumn 46, Issue 18, 2010, Pages 3243-3250

  Le Tourneau, Christophe ^a,b   Faivre, Sandrine ^a,c   Laurence, Valérie ^b   Delbaldo, Catherine ^c,d   Vera, Karina ^c   Girre, Veronique ^b   Chiao, Judy ^e   Armour, Sian ^e   Frame, Sheelagh ^e   Green, Simon R ^e   Gianella Borradori, Athos ^e   Diéras, Veronique ^b   Raymond, Eric ^a,c  

^a BEAUJON HOSPITAL   (France)

^b INSTITUT CURIE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d Mondor Hospital   (France)

^e CYCLACEL LTD   (United Kingdom)

Author keywords

CYC202; Cyclin dependent kinase; Pharmacodynamic; Pharmacokinetic; Phase I trial; Roscovitine; Seliciclib

Indexed keywords

CARBOXYLIC ACID; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 7; CYCLIN DEPENDENT KINASE 9; CYTOKERATIN 18; ROSCOVITINE;

ADULT; ADVANCED CANCER; AGED; APOPTOSIS; ARTICLE; ASTHENIA; CANCER CELL; CELL CYCLE; CELL DEATH; CLINICAL TRIAL; CREATININE BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EXPOSURE; DRUG MONITORING; DRUG RESPONSE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOKALEMIA; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT DURATION; VOMITING;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; DRUG-INDUCED LIVER INJURY; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; METABOLIC DISEASES; MIDDLE AGED; NAUSEA; NEOPLASMS; PURINES; VOMITING;

EID: 78649634707     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2010.08.001     Document Type: Article

References (25)

1. L. Meijer, and E. Raymond Roscovitine and other purines as kinase inhibitors. From starfish oocytes to clinical trials Acc Chem Res 36 2003 417 425
2. M. Serrano, H. Lee, and L. Chin Role of the INK4a locus in tumor suppression and cell mortality Cell 85 1996 27 37
3. J. Tsihlias, L. Kapusta, and J. Slingerland The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer Annu Rev Med 50 1999 401 423
4. J. Bartek, J. Bartkova, and J. Lukas The retinoblastoma protein pathway in cell cycle control and cancer Exp Cell Res 237 1997 1 6
5. S.J. McClue, D. Blake, and R. Clarke In vitro and in vivo antitumor properties of the cyclin dependent kinase inhibitor CYC202 (R-roscovitine) Int J Cancer 102 2002 463 468
6. M. Ljungman, and M.T. Paulsen The cyclin-dependent kinase inhibitor roscovitine inhibits RNA synthesis and triggers nuclear accumulation of p53 that is unmodified at Ser15 and Lys382 Mol Pharmacol 60 2001 785 789
7. M. Mihara, S. Shintani, and A. Kiyota Cyclin-dependent kinase inhibitor (roscovitine) suppresses growth and induces apoptosis by regulating Bcl-x in head and neck squamous cell carcinoma cells Int J Oncol 21 2002 95 101
8. A. Maier, G. Kelter, and A. Gianella-Borradori Antitumor activity of CYC202, a cyclin-dependent kinase inhibitor, in human tumor xenografts in vitro Proc Am Assoc Cancer Res 44 2003 3119
9. H.H. Fiebig, A. Maier, and T. Metz Schedule dependency of combining CYC202 (R-roscovitine), a cyclin-dependent kinase inhibitor, with docetaxel in human tumor xenografts in vivo Proc Am Assoc Cancer Res 9 2003 16
10. F.I. Raynaud, S.R. Whittaker, and P.M. Fischer In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202 Clin Cancer Res 11 2005 4875 4887
11. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
12. G. Kramer, H. Erdal, and H.J. Mertens Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18 Cancer Res 64 2004 1751 1756
13. M.A. Sheard, B. Vojtesek, and M. Simickova Release of cytokeratin-18 and -19 fragments (TPS and CYFRA 21-1) into the extracellular space during apoptosis J Cell Biochem 85 2002 670 677
14. E. Raymond, W.W. ten Bokkel Huinink, and J. Taïeb Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer J Clin Oncol 20 2002 3508 3521
15. C. van Kesteren, A.S. Zandvliet, and M.O. Karlsson Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam Invest New Drugs 23 2005 225 234
16. A.R. Tan, D. Headlee, and R. Messmann Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms J Clin Oncol 20 2002 4074 4082
17. C. Benson, J. White, and J. De Bono A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days Br J Cancer 96 2007 29 37
18. E.I. Heath, K. Bible, R.E. Martell, D.C. Adelman, and P.M. Lorusso A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors Invest New Drugs 26 2008 59 65
19. D.S. Boss, G.K. Schwartz, and M.R. Middleton Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours Ann Oncol 21 2010 884 894
20. S.R. Whittaker, M.I. Walton, and M.D. Garrett The Cyclin-dependent kinase inhibitor CYC202 (R-roscovitine) inhibits retinoblastoma protein phosphorylation, causes loss of Cyclin D1, and activates the mitogen-activated protein kinase pathway Cancer Res 64 2004 262 272
21. R.I. Haddad, L.J. Weinstein, and T.J. Wieczorek A phase II clinical and pharmacodynamic study of E7070 in patients with metastatic, recurrent, or refractory squamous cell carcinoma of the head and neck: modulation of retinoblastoma protein phosphorylation by a novel chloroindolyl sulfonamide cell cycle inhibitor Clin Cancer Res 10 2004 4680 4687
22. B. Kronenberger, M. Wagner, and E. Herrmann Apoptotic cytokeratin 18 neoepitopes in serum of patients with chronic hepatitis C J Viral Hepat 12 2005 307 314 (Pubitemid 40638039)
23. A. Grassi, M. Susca, and S. Ferri Detection of the M30 neoepitope as a new tool to quantify liver apoptosis: timing and patterns of positivity on frozen and paraffin-embedded sections Am J Clin Pathol 121 2004 211 219
24. G. Tramonti, M. Ferdeghini, and C. Donadio Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA 21-1, TPA, and TPS) in patients without evidence of neoplasia Cancer Detect Prev 24 2000 86 90
25. W.S. Hsieh, R. Soo, and B.K. Peh Pharmacodynamic effects of seliciclib, an orally administered cell cycle modulator, in undifferentiated nasopharyngeal cancer Clin Cancer Res 15 2009 1435 1442